Vildagliptin
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the enzymatic degradation of incretin hormones GLP-1 and GIP, prolonging their physiological effects of glucose-dependent insulin secretion stimulation and glucagon suppression to improve glycemic control in type 2 diabetes. It is used as monotherapy or in combination with metformin, sulfonylureas, or insulin for type 2 diabetes management. DPP-4 inhibition provides glucose-dependent hypoglycemic effects with low risk of hypoglycemia.
分子量
303.4000 g/mol
LogP
0.90
TPSA
76.40 Ų
リピンスキーの五則
適合
治療領域
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D構造
Cite this structure
Embed this structure
SMILES
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2
InChI
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
Molecular Formula
C17H25N3O2
HBD / HBA
2 / 4
回転可能結合数
3
重原子数
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the enzymatic degradation of incretin hormones GLP-1 and GIP, prolonging their physiological effects of glucose-dependent insulin secretion stimulation and glucagon suppression to improve glycemic control in type 2 diabetes. It is used as monotherapy or in combination with metformin, sulfonylureas, or insulin for type 2 diabetes management. DPP-4 inhibition provides glucose-dependent hypoglycemic effects with low risk of hypoglycemia.
Yes, Vildagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL142703. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918537. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vildagliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vildagliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vildagliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vildagliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vildagliptin"></drugfyi-drug>